Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.
Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.
复制标题
非家族性高胆固醇血症对洛伐他汀（mevinolin）的治疗反应。
DOI：
--
复制
发表时间：
1986
期刊：
影响因子：
--
通讯作者：
K. Arakawa
中科院分区：
文献类型：
--
作者：
J. Sasaki;Y. Tanabe;K. Saku;M. Takii;K. Arakawa
洛伐他汀（mevinolin），一种有效的3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂，在一项双盲、安慰剂对照的多中心研究中对101例非家族性原发性高胆固醇血症患者进行了研究。剂量范围为10 - 80 mg/d，单次或分次给药。接受40 mg每日两次的患者平均总胆固醇和低密度脂蛋白胆固醇分别降低32%和39%。高密度脂蛋白胆固醇水平倾向于轻微升高，血浆甘油三酯水平中度降低。不良反应归因于洛伐他汀是罕见的，没有病人退出治疗。在这项研究中，洛伐他汀是一个良好的耐受性和有效的药物治疗非家族性高胆固醇血症。
Lovastatin (mevinolin), a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, was investigated in a double-blind, placebo-controlled multicenter study of 101 patients with nonfamilial primary hypercholesterolemia. Dosages varied from 10 to 80 mg/d in single or divided doses. Patients receiving 40 mg twice a day experienced mean total and low-density lipoprotein cholesterol reductions of 32% and 39%, respectively. High-density lipoprotein cholesterol levels tended to rise slightly and plasma triglyceride levels were moderately decreased. Adverse effects attributable to lovastatin were infrequent and no patient was withdrawn from therapy. In this study, lovastatin was a well tolerated and effective agent for the treatment of nonfamilial hypercholesterolemia.